By characterizing these anomalies, scientists have defined new cancer molecular classes, organized under the same diagnosis and the same treatment

IPSOGEN's molecular diagnostic tests, available to hematologists and their patients, today allow personalized treatments for blood cancers.

These tests, developed in close cooperation with clinical centers, highly specialized in this field, provide information on the type of disease (diagnosis, screening), the aggressiveness of the cancer (prognosis), the efficacy of proposed targeted therapies (companion diagnosis) and the course of the cancer being treated (monitoring).

IPSOGEN's main products allow the diagnostic analysis of genetic abnormalities including BCR-ABL (Chronic Myeloid Leukemia), PML-RARA (Promyelocytic Leukemia) and JAK2 V617F (Vaquez disease or Polycythemia Vera, Essential Thrombocythemia and Idiopathic Myelofibrosis). 

The company also proposes other products to clinicians for the diagnostic of rare leukemia forms.